General Information

We are a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs. Our proprietary platform is designed to enable the subcutaneous administration of therapies that have previously been limited to intravenous, or IV, delivery. By moving delivery away from the high-cost healthcare settings typically required for IV administration, we believe our technology reduces overall healthcare costs and advances the quality and convenience of care. Our lead product candidate, Furoscix, consists of our patented subcutaneous formulation of furosemide delivered via our sc2Wear Infusor and is under development for treatment of worsening, or decompensated, heart failure outside of the inpatient setting. We filed a new drug application, or NDA, for Furoscix, with the U.S. Food and Drug Administration, or FDA, in August 2017.

Employees: 28
Founded: 2013
Contact Information
Address 2400 District Avenue, Suite 310, Burlington, MA 01830, US
Phone Number (617) 517-0730
Web Address
View Prospectus: scPharmaceuticals
Financial Information
Market Cap $264.2mil
Revenues $0 mil (last 12 months)
Net Income $-22.3 mil (last 12 months)
IPO Profile
Symbol SCPH
Exchange NASDAQ
Shares (millions): 6.4
Price range $14.00 - $14.00
Est. $ Volume $89.6 mil
Manager / Joint Managers Jefferies/ Leerink Partners/ BMO Capital Markets
CO-Managers -
Expected To Trade: 11/17/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change